Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM
نویسندگان
چکیده
منابع مشابه
Oral Ciprofloxacin Prophylaxis in Patients Undergoing High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation
Background: Antibiotic prophylaxis is usually used in allogenic stem cell transplantation, but its use in Autologous Stem Cell Transplantation (ASCT) is controversial. We evaluated the efficacy of ciprofloxacin prophylaxis in ASCT. Materials and Methods: To identify the efficacy of ciprofloxacin on the incidence of neutropenic fever and its complications, 72 patients had been admitted to Talegh...
متن کاملOral Ciprofloxacin Prophylaxis in Patients Undergoing High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation
Background: Antibiotic prophylaxis is usually used in allogenic stem cell transplantation, but its use in Autologous Stem Cell Transplantation (ASCT) is controversial. We evaluated the efficacy of ciprofloxacin prophylaxis in ASCT. Materials and Methods: To identify the efficacy of ciprofloxacin on the incidence of neutropenic fever and its complications, 72 patients had been admitted to Talegh...
متن کاملTITLE : High dose Y - 90 - Ibritumomab - Tiuxetan with autologous stem cell transplantation in refractory - resistant NHL
BODY: Objectives : Therapeutic options are limited for aggressive high-grade NHL pts not suitable to high dose chemotherapy. Y-90-Ibritumomab-Tiuxetan has already been demonstrated active in elderly pts with resistantrefractory DLBCL at standard activity, however response is usually of short duration. Increasing RIT dose-intensity could improve and prolong efficacy. We evaluated feasibility and...
متن کاملA phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg/kg (day -4) and cyclophosphamide 100 mg/kg (day -2) followed by autologous stem cell transplantation (ASCT) in 31 patients with CD20+ non-Hodgkin lymphoma (NHL). Patients underwent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2...
متن کاملHigh-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.
PURPOSE To evaluate clinical and tumor characteristics in patients receiving high-dose chemotherapy and autologous peripheral stem-cell transplantation (PSCT) or bone marrow transplantation (ABMT) for relapsed or primary refractory non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS One hundred fifty-eight patients with NHL received high-dose chemotherapy and ABMT or PSCT. A multivariate analy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2013
ISSN: 0732-183X,1527-7755
DOI: 10.1200/jco.2013.50.2922